Novartis buys Regulus for $1.7b to grab genetic kidney disease drug
HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG, will acquire Regulus Therapeutics for about $1.7 billion to get access to a.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG, will acquire Regulus Therapeutics for about $1.7 billion to get access to a.
Novartis AG, one of the world’s top 10 pharmaceutical companies in terms of revenue, will acquire US-based Anthos Therapeutics Inc. for $3.1 billion.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com